Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the upcoming launch1 of Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial. Glenmark’s Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, Leucovorin Calcium for Injection, 350 mg/vial, of Hospira, Inc. [NDA 008107]. Glenmark will begin distribution in December 2025.
According to IQVIA® sales data for the 12-month period ending October 2025, the Leucovorin Calcium for Injection, 350 mg/vial market2 achieved annual sales of approximately USD 16.8 million.
Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “We are pleased to announce the upcoming launch of Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial, further expanding our portfolio of products within the institutional channel, while also strengthening our commitment to bring to market quality and affordable alternatives for patients.”
